Cargando…
TEGAFIRI is an effective alternative regimen for the management of recurrent or metastatic colorectal cancer
At present, the global incidence of colorectal cancer is increasing, with numerous individuals succumbing to the disease. The standard treatment strategy for colorectal cancer is curative resection. However, a cure is rarely achieved for metastatic colorectal cancer. Currently, chemotherapy is the m...
Autor principal: | HSU, TZU-CHI |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4314973/ https://www.ncbi.nlm.nih.gov/pubmed/25663857 http://dx.doi.org/10.3892/ol.2015.2855 |
Ejemplares similares
-
Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer
por: Delord, J-P, et al.
Publicado: (2007) -
Response to Modified TEGAFIRI in a Patient with Synchronous Multiple Liver Metastases of Colon Cancer
por: Takanori, Goi, et al.
Publicado: (2011) -
Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study
por: Bajetta, E, et al.
Publicado: (2007) -
Immunotherapy regimens for metastatic colorectal carcinomas
por: Bashir, Babar, et al.
Publicado: (2017) -
An Observational Study of Trifluridine/Tipiracil-Containing Regimen Versus Regorafenib-Containing Regimen in Patients With Metastatic Colorectal Cancer
por: Hsieh, Meng-Che, et al.
Publicado: (2022)